期刊
EMBO MOLECULAR MEDICINE
卷 15, 期 6, 页码 -出版社
WILEY
DOI: 10.15252/emmm.202317463
关键词
gene expression; mitochondria; prostate cancer susceptibility; RNA processing
Prostate cancer is a common and deadly malignancy. Using CRISPR-Cas9 genome editing, researchers introduced a missense variant in the ELAC2 gene into mice, causing prostate enlargement, inflammation, and nodule formation. The study also showed that Elac2 mutation exacerbated the onset and progression of prostate cancer in transgenic mice models.
Prostate cancer is the most commonly diagnosed malignancy and the third leading cause of cancer deaths. GWAS have identified variants associated with prostate cancer susceptibility; however, mechanistic and functional validation of these mutations is lacking. We used CRISPR-Cas9 genome editing to introduce a missense variant identified in the ELAC2 gene, which encodes a dually localised nuclear and mitochondrial RNA processing enzyme, into the mouse Elac2 gene as well as to generate a prostate-specific knockout of Elac2. These mutations caused enlargement and inflammation of the prostate and nodule formation. The Elac2 variant or knockout mice on the background of the transgenic adenocarcinoma of the mouse prostate (TRAMP) model show that Elac2 mutation with a secondary genetic insult exacerbated the onset and progression of prostate cancer. Multiomic profiling revealed defects in energy metabolism that activated proinflammatory and tumorigenic pathways as a consequence of impaired noncoding RNA processing and reduced protein synthesis. Our physiologically relevant models show that the ELAC2 variant is a predisposing factor for prostate cancer and identify changes that underlie the pathogenesis of this cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据